Stocks · News reference

Dr. Reddy's Expands Hospital Portfolio With First-To-Market Sugammadex Injection Launch, Targeting Neuromuscular Blockade Reversal In Surgery Patients

Aug 4, 2026, 6:50 AMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 4, 2026, 6:50 AM
Checked: Aug 4, 2026, 6:50 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 7, 2026, 3:36 PMBenzinga Newsdesk
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination
- Reuters
Read original at benzinga
NVS RDY
BenzingaJul 29, 2026, 4:30 PMBenzinga Newsdesk
Dr. Reddy’s Laboratories Announces U.S. FDA Completes Inspection at Srikakulam Unit, Issues Form 483
Read original at benzinga
RDY
BenzingaJul 22, 2026, 6:12 PMVandana Singh
Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat
Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutide issues & Trump tariff plans weigh on shares.
Read original at benzinga
RDY